• Publications
  • Influence
MUC1 immunobiology: from discovery to clinical applications.
  • 209
  • 9
Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer
Purpose: Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors. We aimed to identify plasma miRNAsExpand
  • 140
  • 6
  • PDF
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1
Immunity to tumor Ags in patients is typically weak and not therapeutic. We have identified a new mechanism by which potentially immunogenic glycoprotein tumor Ags, such as MUC1, fail to stimulateExpand
  • 167
  • 6
  • PDF
A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells
SUMMARY Endometriosis is defined by the presence of tissue implants resembling endometrial glands outside of the uterus, at ectopic sites, frequently on the ovarian surface. The ectopic lesions areExpand
  • 40
  • 6
  • PDF
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as theExpand
  • 50
  • 5
  • PDF
Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells
In contrast to protein antigens, processing of glycoproteins by dendritic cells (DCs) for presentation to T cells has not been well studied. We developed mouse T cell hybridomas to study processingExpand
  • 157
  • 2
Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Purpose: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions.Expand
  • 46
  • 2
  • PDF
Glycoprotein tumor antigens for immunotherapy of breast cancer.
Continued progress in breast cancer immunotherapy, in particular breast cancer vaccines, depends on the identification of target molecules aberrantly expressed on breast cancer cells. Many differentExpand
  • 35
  • 2
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice
Abstract Human adenocarcinomas overexpress a hypoglycosylated, tumor-associated form of the mucin-like glycoprotein MUC1 containing abnormal mono- and disaccharide antigens, such as Tn, sialyl-Tn,Expand
  • 42
  • 2
Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade
Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting thatExpand
  • 26
  • 2